Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $6.00 price objective on the stock.

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Trading Up 8.1 %

NASDAQ TLPH opened at $0.67 on Tuesday. The business’s 50-day moving average price is $0.66 and its 200 day moving average price is $0.82. Talphera has a twelve month low of $0.50 and a twelve month high of $1.61. The company has a market capitalization of $11.41 million, a PE ratio of -0.97 and a beta of 0.28.

Institutional Investors Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC purchased a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned approximately 11.73% of Talphera as of its most recent SEC filing. 37.67% of the stock is owned by hedge funds and other institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.